Anaemia is common and predicts mortality in diabetic nephropathy

QJM: An International Journal of Medicine

Volumn 100, Issue 10, 2007, Pages 641-647

  Joss, N ^a   Patel, R ^a   Paterson, K ^a   Simpson, K ^a   Perry, C ^a   Stirling, Cath ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; ECHOGRAPHY; ELECTRONIC MEDICAL RECORD; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE FACILITY; HUMAN; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT REFERRAL; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; SURVIVAL RATE;

EID: 35148832530     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm080     Document Type: Article

References (38)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 1997; 14(Suppl. 5):S1-85.
2. UK Renal registry. [http://www.renalorg.uk]
3. US Renal Data System. USRDS 2005 Annual Report Atlas of End-Stage Renal disease in the United States. Bethesda MD National Institutes of Health, National Institute of Diabetes and digestive and Kidney Diseases, 2006.
4. St Vincent Declaration. http://www.show.scot.nhs.uk/crag/topics/diabetes/ vincent.htm]
5. National Service Framework for renal services, part I and part II. [http://www.dh.gov.uk/policyandguidance/healthand socialcaretopics/renal/ renalinformation/renalinformationarticle/fs/en]
6. The UK Chronic Kidney Disease Guidelines 2005. [http://www.renal.org/ CKDguide/ckd.html]
7. Lhotta K, Zoebl M, Mayer G, Kronenberg F. Late referral defined by renal function: Association with morbidity and mortality. J Nephrol 2003; 16:855-61.
8. Roderick P, Jones C, Drey N, et al. Late referral for end-stage renal disease: A region-wide survey in the south west of England. Nephrol Dial Transplant 2002; 17:1252-9.
9. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34:125-34.
10. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values, of 36 to 39%. J Am Soc Nephrol 2001; 12 2465-73.
11. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16 1803-10.
12. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996; 27:548-56.
13. Valderrabano F, Horl WH, Jacobs C. et al. European best [ractice guidelines 1-4: Evaluating anaemia and initiating treatment. Nephrol Dial Transplant 2000; 15(Suppl. 4):8-14.
14. Jacobs C, Horl WH, Macdougall IC, et al. European best practice guidelines 5: Target haemoglobin. Nephrol Dial Transplant 2000; 15(Suppl 4):15-19.
15. NKF-K/DOQI Clinical Practice Guidelines for Anaemia of Chronic kidney Disease. Am J Kidney Dis 2001; 37:S182.
16. NKF-K/DOQI Clinical Practice Guidelines for Anaemia of Chronic Kidney Disease. Am J Kidney Dis 2006; 47:S1.
17. NICE guideline. Anaemia management in chronic kidney disease. [http://guidance.nice.org.uk/cg39/2c=91526].
18. Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM. Vascular Disease and Survival in patients with type 2 diabetes and nephropathy. Br J Diabetes Vasc Dis 2002; 2:137-42.
19. Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM. Diabetic nephropathy: How effective is treatment in clinical practice? Q J Med 2002; 95:41-9.
20. Levey AS, Green TJ, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11:A0828.
21. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 1987; 294:1443-7.
22. Management of diabetic renal disease. The Scottish Intercollegiate Guidelines Network (SIGN), 1997.
23. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24:495-99.
24. Ishimura E, Nishizawa Y, Okuno S, et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 1998; 11:83-6.
25. Al Khoury S, Afzali B, Shah N, et al. Anaemia in diabetic patients with chronic kidney disease-prevalence and predictors. Diabetologia 2006; 49:1183-9.
26. Dikow R, Schwenger V, Schomig M, Ritz E. How should we manage anaemia in patients with diabetes? Nephrol Dial Transplant 2002; 17(Suppl. 1):67-72.
27. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
28. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13 1206-10.
29. London GM, Zins B, Pannier B, et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36:878-82.
30. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 2001; 37:1775-80.
31. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28:53-61.
32. Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40:27-33.
33. Strippoli GFM., Manno C, Schena FP, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease (Cochrane Review). The Cochrane Database of Systematic Reviews, 2006.
34. Drueke TB, Locatelli F, Clyne N, Eckardt K, MacDougall IC, Tsakiris D, Burger H, Scherhag A. Normalisation of haemoglobin level in patients with chronic kidney disease and anaemia. N Engl J Med 2006; 355 2072-84.
35. Singh AK, Szczech L, Tang K, Barnhart H, Saap S, Wolfson M, Reddan D. Correction of anaemia with epoietin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-98.
36. Laville M. New strategies in anaemia management:ACORD (Anaemia CORrection in Diabetes) trial. Acta Diabetologica 2004; 41 (Suppl 1):S18-22.
37. Mix TC, Brenner RM, Cooper ME, et al. Rationale- Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005; 149:408-13.
38. Joss N, Ferguson C, Brown C, Deighan CJ, Paterson KR, Boulton-Jones JM. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. Q J Med 2004; 97:219-27.